Molecure (1B1) Stock Overview
A biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
1B1 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Molecure S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł1.58 |
| 52 Week High | zł2.02 |
| 52 Week Low | zł1.15 |
| Beta | 1 |
| 1 Month Change | 18.39% |
| 3 Month Change | 24.53% |
| 1 Year Change | -1.00% |
| 3 Year Change | -64.44% |
| 5 Year Change | -84.41% |
| Change since IPO | -85.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1B1 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 14.5% | -1.3% | -2.2% |
| 1Y | -1.0% | 41.8% | 3.4% |
Return vs Industry: 1B1 underperformed the German Pharmaceuticals industry which returned 40.8% over the past year.
Return vs Market: 1B1 underperformed the German Market which returned 4% over the past year.
Price Volatility
| 1B1 volatility | |
|---|---|
| 1B1 Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 12.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 1B1 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 1B1's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 71 | Marcin Szumowski | molecure.com |
Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-40 for the treatment of cancer; and Deubiquitinase program.
Molecure S.A. Fundamentals Summary
| 1B1 fundamental statistics | |
|---|---|
| Market cap | €35.03m |
| Earnings (TTM) | -€3.61m |
| Revenue (TTM) | €1.50m |
Is 1B1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1B1 income statement (TTM) | |
|---|---|
| Revenue | zł6.52m |
| Cost of Revenue | zł23.08m |
| Gross Profit | -zł16.56m |
| Other Expenses | -zł869.90k |
| Earnings | -zł15.69m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Sep 30, 2026
| Earnings per share (EPS) | -0.76 |
| Gross Margin | -253.99% |
| Net Profit Margin | -240.64% |
| Debt/Equity Ratio | 6.2% |
How did 1B1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/14 08:00 |
| End of Day Share Price | 2026/09/14 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Molecure S.A. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Beata Szparaga-Wasniewska | Biuro maklerskie mBanku |
| Lukasz Kosiarski | Ipopema Securities S.A. |
| Dawid Górzynski | PKO BP Securities |